FDA Approves Invokamet XR (canagliflozin/metformin) for Type 2 Diabetes
FDA approves new once-daily pill for type 2 diabetes
The FDA approved Invokamet XR, a combination of canagliflozin and metformin extended-release, as an adjunct to diet and exercise to improve …
The FDA approved Invokamet XR, a combination pill for type 2 diabetes. It helps control blood sugar and may reduce heart and kidney risks in…
FDA Approves Jentadueto XR (linagliptin/metformin) for Type 2 Diabetes
FDA approves Jentadueto XR for adults with type 2 diabetes.
The FDA approved Jentadueto XR (linagliptin and metformin hydrochloride) as an adjunct to diet and exercise to improve glycemic control in a…
The FDA approved Jentadueto XR, a once-daily pill that combines two diabetes medicines, to help adults with type 2 diabetes control blood su…
FDA Approves Xigduo XR (dapagliflozin/metformin) for Type 2 Diabetes and Related Indications
FDA approves new combination pill Xigduo XR for type 2 diabetes
The FDA approved Xigduo XR (dapagliflozin and metformin HCl extended-release) to improve glycemic control in adults and pediatric patients a…
The FDA approved Xigduo XR, a once-daily pill combining two diabetes medicines, for adults and children 10 and older with type 2 diabetes. I…
FDA Approves Invokamet (canagliflozin/metformin) for Type 2 Diabetes
FDA approves Invokamet for type 2 diabetes in adults and children 10 and older.
The FDA approved Invokamet (canagliflozin and metformin HCl) as an adjunct to diet and exercise to improve glycemic control in adults and pe…
The FDA approved Invokamet, a combination of canagliflozin and metformin, to improve blood sugar control in people with type 2 diabetes. It …
FDA Approves Zituvimet XR (sitagliptin/metformin HCl ER) for Type 2 Diabetes
FDA approves Zituvimet XR for adults with type 2 diabetes.
The FDA approved Zituvimet XR (sitagliptin and metformin HCl extended-release) as an adjunct to diet and exercise to improve glycemic contro…
The FDA approved Zituvimet XR, a once-daily pill combining sitagliptin and extended-release metformin, to improve blood sugar control in adu…
FDA Approves Trijardy XR (empagliflozin, linagliptin, metformin HCl) for Type 2 Diabetes
FDA approves new combination pill Trijardy XR for type 2 diabetes
The FDA approved Trijardy XR, a fixed-dose combination of empagliflozin, linagliptin, and metformin HCl, as an adjunct to diet and exercise …
The FDA approved Trijardy XR, a once-daily pill combining three diabetes medicines, to improve blood sugar control in adults with type 2 dia…
FDA Approves Janumet (sitagliptin/metformin) for Type 2 Diabetes
FDA approves Janumet to improve blood sugar in type 2 diabetes
The FDA approved Janumet, a fixed-dose combination of sitagliptin and metformin, as an adjunct to diet and exercise to improve glycemic cont…
The FDA approved Janumet, a combination pill for adults with type 2 diabetes, to help control blood sugar when used with diet and exercise. …
SGLT2 inhibitors raise hematocrit by 2.29% and hemoglobin by 0.51 g/dL in type 2 diabetes
SGLT2 Inhibitors Linked to Higher Blood Levels in Diabetes Patients
This meta-analysis of 10 studies (including RCTs and real-world data) found that SGLT2 inhibitors consistently increase hemoglobin and hemat…
New data shows SGLT2 inhibitors are linked to higher hemoglobin and hematocrit levels in adults with Type 2 Diabetes.
Ramped position provides comparable first-pass success to sniffing position for intubating obese patients
Ramped position may reduce intubation attempts for obese patients
This meta-analysis of 938 patients evaluated the impact of a ramped position versus a sniffing position during endotracheal intubation in ob…
A new review shows that using a ramped position can lead to fewer attempts when placing breathing tubes in patients with obesity.
Glucagon-like peptide-1 receptor agonists associated with reduced Parkinson's disease risk in type 2 diabetes
New Data Suggests Specific Diabetes Medications May Lower Risk of Parkinson Disease
Researchers analyzed real-world data to evaluate the association between GLP-1RAs and Parkinson's disease risk in patients with type 2 diabe…
A large study shows that people with type 2 diabetes taking GLP-1 receptor agonists may have a lower risk of developing Parkinson disease.
Tirzepatide reduces inflammatory markers and improves metabolic biomarkers in patients with obesity
Tirzepatide reduces markers of inflammation in people with obesity
This post hoc analysis of a randomized controlled trial involving 392 people with overweight or obesity found that tirzepatide significantly…
A new analysis shows that tirzepatide may lower key markers of inflammation and metabolic stress for people living with weight and type 2 di…
Curcumin raises femoral bone density in animal osteoporosis models, meta-analysis finds
Curcumin shows potential to improve bone density in animal models
This meta-analysis of 23 preclinical studies in animal models of osteoporosis found that curcumin monotherapy significantly increased femora…
New research suggests that curcumin may help strengthen bones and protect against osteoporosis in early laboratory studies.